Herceptin: monoclonal antibody therapy for metastatic breast cancer
... The clinical benefits of Herceptin® were shown in two clinical trials (Table 1).14-16 In a randomized, controlled trial, 469 patients with metastatic disease over-expressing HER2 were assigned to receive chemotherapy (CRx) alone (either paclitaxel (T) or doxorubicin plus cyclophosphamide (AC)) or ch ...
... The clinical benefits of Herceptin® were shown in two clinical trials (Table 1).14-16 In a randomized, controlled trial, 469 patients with metastatic disease over-expressing HER2 were assigned to receive chemotherapy (CRx) alone (either paclitaxel (T) or doxorubicin plus cyclophosphamide (AC)) or ch ...
among Iranian Breast Cancer Patients, a Policy Brief
... • Lack of appropriate information technology infrastructure for establishment of effective communication among sections involved in the management of expensive drugs: These infrastructures have major deficiencies in terms of both inter-organization information system (IOIS) and patient electronic da ...
... • Lack of appropriate information technology infrastructure for establishment of effective communication among sections involved in the management of expensive drugs: These infrastructures have major deficiencies in terms of both inter-organization information system (IOIS) and patient electronic da ...
Biotech drugs: biological therapeutic agents
... and promising results are being reported in breast adenocarcinomas.14 It is important to classify patients as HER2-positive to ensure beneficial responses. In B-cell nonHodgkin’s Lymphoma the surface marker CD20 is targeted (Rituximab) initiating an antibody-dependent and complementdependent cell me ...
... and promising results are being reported in breast adenocarcinomas.14 It is important to classify patients as HER2-positive to ensure beneficial responses. In B-cell nonHodgkin’s Lymphoma the surface marker CD20 is targeted (Rituximab) initiating an antibody-dependent and complementdependent cell me ...
How clinical trials create breakthroughs in care
... – Results of first study confirm role for HER2 targeted therapy after progression on Herceptin – Is it better than Herceptin? – Can it add to benefit of Herceptin – Are there particular types of tumors that are better treated with one or the other – Lapatinib being tested in adjuvant setting ...
... – Results of first study confirm role for HER2 targeted therapy after progression on Herceptin – Is it better than Herceptin? – Can it add to benefit of Herceptin – Are there particular types of tumors that are better treated with one or the other – Lapatinib being tested in adjuvant setting ...
Alternative Therapy in Cancer Miracle or Myth?
... to prolong life and alleviate suffering to improve the quality of life for a patient with no implied impact upon their survival ...
... to prolong life and alleviate suffering to improve the quality of life for a patient with no implied impact upon their survival ...
Pharmacologic insights into the future of trastuzumab
... A combination of factors has been responsible for improvements in cancer survival and cure rates. In addition to new therapies with novel/genetic targets, these include improvements in drug delivery, new schedules/sequencing of drug administration and the identification of combination therapies with ...
... A combination of factors has been responsible for improvements in cancer survival and cure rates. In addition to new therapies with novel/genetic targets, these include improvements in drug delivery, new schedules/sequencing of drug administration and the identification of combination therapies with ...
Biomarkers: Signals of hope from the personalized treatment of cancer
... facilitated Medicine in creating targeted or “personalized” therapies, such as Herceptin (trastuzumab, Roche), which inhibit tumor growth and increases survival in these patients. It is currently known that in a group of patients with an early diagnosis of HER2-positive breast cancer, Herceptin redu ...
... facilitated Medicine in creating targeted or “personalized” therapies, such as Herceptin (trastuzumab, Roche), which inhibit tumor growth and increases survival in these patients. It is currently known that in a group of patients with an early diagnosis of HER2-positive breast cancer, Herceptin redu ...
Slide 1
... Human epidermal growth factor (HER2, ERBB2) overexpressed in ~25% breast cancers, marker of poor prognosis Trastuzumab: humanized monoclonal antibody targeting ERBB2, often used in combination with taxanes Multiple randomized trials show trastuzumab benefit in ERBB2+ breast cancers, 80% of trials sh ...
... Human epidermal growth factor (HER2, ERBB2) overexpressed in ~25% breast cancers, marker of poor prognosis Trastuzumab: humanized monoclonal antibody targeting ERBB2, often used in combination with taxanes Multiple randomized trials show trastuzumab benefit in ERBB2+ breast cancers, 80% of trials sh ...
Use of Chemotherapy plus a Monoclonal Antibody (Trastuzumab
... chemotherapy for metastatic disease were eligible for the study. • The level of expression of HER2 was determined by immunohistochemical analysis in a central laboratory. • Only patients who had weak-to-moderate staining of the entire tumor-cell membrane for HER2 (referred to as a score of 2+) or mo ...
... chemotherapy for metastatic disease were eligible for the study. • The level of expression of HER2 was determined by immunohistochemical analysis in a central laboratory. • Only patients who had weak-to-moderate staining of the entire tumor-cell membrane for HER2 (referred to as a score of 2+) or mo ...
786 sub cut herceptin final
... stimulates their growth. Trastuzumab (Herceptin®) is one of a group of cancer drugs called monoclonal antibodies. Monoclonal antibodies are sometimes called targeted therapies because they work by ‘targeting’ specific proteins (receptors) on the surface of cells. Trastuzumab (Herceptin®) locks onto ...
... stimulates their growth. Trastuzumab (Herceptin®) is one of a group of cancer drugs called monoclonal antibodies. Monoclonal antibodies are sometimes called targeted therapies because they work by ‘targeting’ specific proteins (receptors) on the surface of cells. Trastuzumab (Herceptin®) locks onto ...
The Oncologist, Vol. 12, No. 3, 325
... Four second generation EGFR inhibitors are now entering clinical trials EKB-569, HKI-272, CI-1033, and ZD6474 ...
... Four second generation EGFR inhibitors are now entering clinical trials EKB-569, HKI-272, CI-1033, and ZD6474 ...
The Oncologist, Vol. 12, No. 3, 325
... Four second generation EGFR inhibitors are now entering clinical trials EKB-569, HKI-272, CI-1033, and ZD6474 ...
... Four second generation EGFR inhibitors are now entering clinical trials EKB-569, HKI-272, CI-1033, and ZD6474 ...
A novel, highly potent HER2-targeted antibody
... 1+/2+). XMT-1522 is an anti-HER2 ADC that uses a novel, human anti-HER2 antibody optimized for cytotoxic payload delivery, and is non-competitive with trastuzumab or pertuzumab for HER2 binding. Each antibody is conjugated to ~15 proprietary auristatin molecules using Fleximer, a biodegradable hydro ...
... 1+/2+). XMT-1522 is an anti-HER2 ADC that uses a novel, human anti-HER2 antibody optimized for cytotoxic payload delivery, and is non-competitive with trastuzumab or pertuzumab for HER2 binding. Each antibody is conjugated to ~15 proprietary auristatin molecules using Fleximer, a biodegradable hydro ...
New Approval Mechanism for Breast Cancer using pathologic
... • Uncertainty about magnitude of improvement in pCR needed to improve EFS/OS – May vary by breast cancer subtype – Some patients with pCR will relapse and many with residual disease will not ...
... • Uncertainty about magnitude of improvement in pCR needed to improve EFS/OS – May vary by breast cancer subtype – Some patients with pCR will relapse and many with residual disease will not ...
Anti HER2 mAbs
... Jr. The film is based on the true life story of Dr. Dennis Slamon. New York (NY): Random House, 1998. 214 pp., illus. ISBN 0-679-45702-X ...
... Jr. The film is based on the true life story of Dr. Dennis Slamon. New York (NY): Random House, 1998. 214 pp., illus. ISBN 0-679-45702-X ...
open - PAGE meetings
... HER2-positive cancer B. Bender (1,2), D. Leipold (2), L. Liu (2), K. Xu (2), B.-Q. Shen (2), L.E. Friberg (1), J. Tibbitts (2) (1) Dept of Pharmaceutical Biosciences, Uppsala University, Sweden, (2) Genentech Inc, San Francisco, CA ...
... HER2-positive cancer B. Bender (1,2), D. Leipold (2), L. Liu (2), K. Xu (2), B.-Q. Shen (2), L.E. Friberg (1), J. Tibbitts (2) (1) Dept of Pharmaceutical Biosciences, Uppsala University, Sweden, (2) Genentech Inc, San Francisco, CA ...
Additional file 2 Name: Trastuzumab (DB00072) Description: For
... protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. ...
... protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. ...
2015 department of medicine research day
... In addition, exploratory measures of efficacy will be performed throughout both phases of the study. Mechanism: KD019 (formerly named XL647) is a new chemical entity that inhibits multiple tyrosine kinases (TKs) ErbB family members [EGFR and HER2/ErbB2], vascular endothelial growth factor receptor [ ...
... In addition, exploratory measures of efficacy will be performed throughout both phases of the study. Mechanism: KD019 (formerly named XL647) is a new chemical entity that inhibits multiple tyrosine kinases (TKs) ErbB family members [EGFR and HER2/ErbB2], vascular endothelial growth factor receptor [ ...
Trastuzumab
... Recombinant humanized monoclonal antibody directed against the extracellular domain of the HER-2/neu human epidermal growth factor receptor. This receptor is overexpressed in several human cancers, including 25%–30% of breast cancers. Precise mechanism(s) of action remains unknown. Downregulates exp ...
... Recombinant humanized monoclonal antibody directed against the extracellular domain of the HER-2/neu human epidermal growth factor receptor. This receptor is overexpressed in several human cancers, including 25%–30% of breast cancers. Precise mechanism(s) of action remains unknown. Downregulates exp ...
